Faeth Therapeutics (FTH)
Market Price (11/6/2026): $19.64 | Market Cap: $507.6 MilSector: Health Care | Industry: Biotechnology
Faeth Therapeutics (FTH)
Market Price (11/6/2026): $19.64Market Cap: $507.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -64% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -216 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46% High stock price volatilityVol 12M is 107% Key risksFTH key risks include [1] the potential clinical and regulatory failure of its lead drug candidates like SNS-101 and [2] a heavy reliance on its unproven proprietary ImmunoPhage and biologics platforms. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -64% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -216 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46% |
| High stock price volatilityVol 12M is 107% |
| Key risksFTH key risks include [1] the potential clinical and regulatory failure of its lead drug candidates like SNS-101 and [2] a heavy reliance on its unproven proprietary ImmunoPhage and biologics platforms. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 11/1/2026
Faeth Therapeutics (FTH) stock has lost about 25% since 7/31/2026 because of the following key factors:
1. Widening Net Losses and Increased Operating Expenses.
Faeth Therapeutics reported a significant increase in net loss for its fiscal Q3 2026 (ended September 30, 2026), widening to $20.4 million, or $0.79 per basic and diluted share, compared to a net loss of $4.6 million, or $3.62 per share, in fiscal Q3 2025. This substantial increase was driven by rising operational costs, with Research and Development (R&D) expenses growing to $11.7 million in fiscal Q3 2026 from $2.5 million in fiscal Q3 2025, and General and Administrative (G&A) expenses increasing to $10.4 million from $2.3 million over the same period. These figures, particularly the larger absolute net loss, likely contributed to investor apprehension during the specified period.
2. Concerns Regarding PIKTOR's Tolerability Profile.
Despite positive developments like FDA Fast Track designation for PIKTOR, Faeth's lead investigational drug, analyst concerns have been highlighted regarding the broader tolerability profile of the PI3K/AKT/mTOR class, to which PIKTOR belongs. Specific "red flags" noted include a dose-limiting grade 4 renal failure from hyperglycemia and a 26% rate of grade ≥3 neutropenia. These significant adverse events raise questions about PIKTOR's clinical trial success and potential commercial viability, leading to increased risk perception among investors.
Show more
Faeth Therapeutics (FTH) stock has lost about 25% since 7/31/2026 because of the following key factors:
1. Widening Net Losses and Increased Operating Expenses.
Faeth Therapeutics reported a significant increase in net loss for its fiscal Q3 2026 (ended September 30, 2026), widening to $20.4 million, or $0.79 per basic and diluted share, compared to a net loss of $4.6 million, or $3.62 per share, in fiscal Q3 2025. This substantial increase was driven by rising operational costs, with Research and Development (R&D) expenses growing to $11.7 million in fiscal Q3 2026 from $2.5 million in fiscal Q3 2025, and General and Administrative (G&A) expenses increasing to $10.4 million from $2.3 million over the same period. These figures, particularly the larger absolute net loss, likely contributed to investor apprehension during the specified period.
2. Concerns Regarding PIKTOR's Tolerability Profile.
Despite positive developments like FDA Fast Track designation for PIKTOR, Faeth's lead investigational drug, analyst concerns have been highlighted regarding the broader tolerability profile of the PI3K/AKT/mTOR class, to which PIKTOR belongs. Specific "red flags" noted include a dose-limiting grade 4 renal failure from hyperglycemia and a 26% rate of grade ≥3 neutropenia. These significant adverse events raise questions about PIKTOR's clinical trial success and potential commercial viability, leading to increased risk perception among investors.
Show more
Updated on 11/1/2026
Faeth Therapeutics (FTH) stock has lost about 25% since 7/31/2026 because of the following key factors:
1. Widening Net Losses and Increased Operating Expenses.
Faeth Therapeutics reported a significant increase in net loss for its fiscal Q3 2026 (ended September 30, 2026), widening to $20.4 million, or $0.79 per basic and diluted share, compared to a net loss of $4.6 million, or $3.62 per share, in fiscal Q3 2025. This substantial increase was driven by rising operational costs, with Research and Development (R&D) expenses growing to $11.7 million in fiscal Q3 2026 from $2.5 million in fiscal Q3 2025, and General and Administrative (G&A) expenses increasing to $10.4 million from $2.3 million over the same period. These figures, particularly the larger absolute net loss, likely contributed to investor apprehension during the specified period.
2. Concerns Regarding PIKTOR's Tolerability Profile.
Despite positive developments like FDA Fast Track designation for PIKTOR, Faeth's lead investigational drug, analyst concerns have been highlighted regarding the broader tolerability profile of the PI3K/AKT/mTOR class, to which PIKTOR belongs. Specific "red flags" noted include a dose-limiting grade 4 renal failure from hyperglycemia and a 26% rate of grade ≥3 neutropenia. These significant adverse events raise questions about PIKTOR's clinical trial success and potential commercial viability, leading to increased risk perception among investors.
3. Increased Cash Burn and Potential for Future Dilution.
The company experienced a notable increase in its cash burn rate. Cash, cash equivalents, and marketable securities decreased from $186.4 million as of June 30, 2026 (fiscal Q2 2026) to $174.8 million as of September 30, 2026 (fiscal Q3 2026). With substantial and increasing operating expenses and no product revenue, this cash depletion raises concerns about the company's financial runway. Investors may be anticipating the need for future equity financing, which could lead to dilution for existing shareholders, thereby putting downward pressure on the stock price.
Show less
Faeth Therapeutics (FTH) stock has lost about 25% since 7/31/2026 because of the following key factors:
1. Widening Net Losses and Increased Operating Expenses.
Faeth Therapeutics reported a significant increase in net loss for its fiscal Q3 2026 (ended September 30, 2026), widening to $20.4 million, or $0.79 per basic and diluted share, compared to a net loss of $4.6 million, or $3.62 per share, in fiscal Q3 2025. This substantial increase was driven by rising operational costs, with Research and Development (R&D) expenses growing to $11.7 million in fiscal Q3 2026 from $2.5 million in fiscal Q3 2025, and General and Administrative (G&A) expenses increasing to $10.4 million from $2.3 million over the same period. These figures, particularly the larger absolute net loss, likely contributed to investor apprehension during the specified period.
2. Concerns Regarding PIKTOR's Tolerability Profile.
Despite positive developments like FDA Fast Track designation for PIKTOR, Faeth's lead investigational drug, analyst concerns have been highlighted regarding the broader tolerability profile of the PI3K/AKT/mTOR class, to which PIKTOR belongs. Specific "red flags" noted include a dose-limiting grade 4 renal failure from hyperglycemia and a 26% rate of grade ≥3 neutropenia. These significant adverse events raise questions about PIKTOR's clinical trial success and potential commercial viability, leading to increased risk perception among investors.
3. Increased Cash Burn and Potential for Future Dilution.
The company experienced a notable increase in its cash burn rate. Cash, cash equivalents, and marketable securities decreased from $186.4 million as of June 30, 2026 (fiscal Q2 2026) to $174.8 million as of September 30, 2026 (fiscal Q3 2026). With substantial and increasing operating expenses and no product revenue, this cash depletion raises concerns about the company's financial runway. Investors may be anticipating the need for future equity financing, which could lead to dilution for existing shareholders, thereby putting downward pressure on the stock price.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -26.9% change in FTH stock from 7/31/2026 to 11/5/2026 was primarily driven by a -95.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.24 | 19.92 | -26.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 26 | -95.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| FTH | -26.9% | |
| Market (SPY) | -1.9% | 7.4% |
| Sector (XLV) | 13.8% | 12.8% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| FTH | ||
| Market (SPY) | 2.3% | 11.7% |
| Sector (XLV) | 27.2% | -4.5% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 11/5/2026| Return | Correlation | |
|---|---|---|
| FTH | ||
| Market (SPY) | 8.4% | 11.7% |
| Sector (XLV) | 29.8% | -4.5% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2023 to 11/5/2026| Return | Correlation | |
|---|---|---|
| FTH | ||
| Market (SPY) | 81.3% | 11.7% |
| Sector (XLV) | 55.5% | -4.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| FTH Return | - | - | - | - | - | 20% | 20% |
| Peers Return | -28% | -36% | -45% | -42% | 125% | -53% | -85% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| FTH Win Rate | - | - | - | - | - | 67% | |
| Peers Win Rate | 31% | 44% | 42% | 35% | 60% | 24% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| FTH Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -56% | -61% | -68% | -68% | -57% | -69% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ETRA, GOSS, HYFT, JAGX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/5/2026 (YTD)
How Low Can It Go
FTH has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
FTH has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Faeth Therapeutics (FTH)
Faeth Therapeutics (FTH) is a biopharmaceutical company dedicated to the discovery and development of immunotherapies, with an initial and primary focus on creating innovative treatments for cancer. The company leverages advanced, proprietary technology platforms designed to activate and direct the body's immune system to combat diseases, particularly within the challenging oncology landscape.
The company's core technological assets include its ImmunoPhage platform, an approach that utilizes bacteriophages to induce a focused and coordinated innate and adaptive immune response. Additionally, Faeth employs its Tumor Microenvironment Activated Biologics platform, which aims to unleash the anti-tumor potential of T-cells through human monoclonal antibodies selectively active in the tumor microenvironment, targeting immune checkpoints or other critical immune pathways. Key product candidates in development include SNS-101, a monoclonal antibody for cancer treatment, and SNS-401-NG, an ImmunoPhage vaccine designed to target multiple tumor antigens. Faeth also maintains a collaborative research and development effort with The University of Washington for a Merkel cell carcinoma vaccine.
Faeth Therapeutics primarily serves the global oncology market, aiming to provide novel therapeutic options for patients afflicted with various types of cancer. By developing advanced immunotherapies, the company seeks to address significant unmet medical needs within the patient population requiring cutting-edge cancer treatments.
AI Analysis | Feedback
null
AI Analysis | Feedback
Please note: The background information provided describes Sensei Biotherapeutics, Inc., which trades under the symbol FTH. The products listed below are for Sensei Biotherapeutics, Inc.
- ImmunoPhage platform: An immunotherapy approach designed to utilize bacteriophage to induce focused and coordinated innate and adaptive immune responses for cancer treatment.
- Tumor Microenvironment Activated Biologics platform: A platform designed to unleash the anti-tumor potential of T-cells through human monoclonal antibodies selectively active in the tumor microenvironment.
- SNS-101: A monoclonal antibody currently under development for the treatment of cancer.
- SNS-401-NG: An ImmunoPhage vaccine specifically designed to target multiple tumor antigens.
- Merkel cell carcinoma vaccine: A research and development collaboration with The University of Washington for a vaccine targeting Merkel cell carcinoma.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Anand Parikh, Chairman, President and Chief Executive Officer
Anand Parikh is a co-founder of Faeth Therapeutics, which he helped found in 2019. He previously held multiple executive roles at Virta Health, a therapeutics company focused on nutrition to treat type 2 diabetes, starting in May 2015. These roles included General Counsel, Head of Finance, and Head of Human Resources, and he also served as CFO of Virta Health, a company valued at $2 billion. Faeth Therapeutics is backed by prominent institutional investors such as Khosla Ventures, Future Ventures, S2G Ventures, KdT Ventures, Digitalis Ventures, and Cantos Ventures. Virta Health also raised significant funding from investors. Parikh began his career as a corporate attorney.
Brian Stephenson, Ph.D., CFA, Chief Financial Officer
Brian Stephenson was appointed Chief Financial Officer of Faeth Therapeutics effective June 12, 2026. Prior to this role, he served as the company's Head of Operations and Finance and was previously the Chief Financial Officer of BridgeBio Pharma, Inc.
Oliver Maddocks, Ph.D., Chief Scientific Officer
Oliver Maddocks is a co-founder of Faeth Therapeutics and a cancer-metabolism researcher.
Debbie Chirnomas, M.D., M.P.H., Chief Medical Officer
Debbie Chirnomas serves as the Chief Medical Officer for Faeth Therapeutics.
AI Analysis | Feedback
Key Risks to the Business
- Clinical Development and Regulatory Approval Risk: As a biopharmaceutical company focused on the discovery and development of immunotherapies, Faeth Therapeutics (Sensei Biotherapeutics, Inc.) faces significant risks related to the successful completion of clinical trials and obtaining regulatory approvals for its drug candidates, such as SNS-101 and SNS-401-NG. The failure of any drug candidate to demonstrate safety and efficacy in clinical trials, or the inability to secure necessary regulatory approvals, would severely impact the company's future prospects and financial viability.
- Reliance on Proprietary Platforms and Unproven Technology Risk: The company's core strategy is heavily reliant on its proprietary ImmunoPhage platform and Tumor Microenvironment Activated Biologics platform. The scientific novelty and unproven nature of these platforms in generating successful commercial products introduce inherent risks. If these platforms do not consistently yield viable drug candidates or if the underlying scientific principles prove to be less effective than anticipated, the company's ability to develop its pipeline and compete in the market could be substantially undermined.
- Intellectual Property Protection Risk: Faeth Therapeutics' (Sensei Biotherapeutics, Inc.'s) value is significantly tied to its intellectual property, including its proprietary platforms and specific drug candidates. The risk of failing to obtain, maintain, or adequately protect its patents and other intellectual property rights is substantial. Challenges to existing patents, the inability to secure new patents, or infringement by competitors could lead to a loss of competitive advantage and hinder the company's ability to commercialize its innovations.
AI Analysis | Feedback
null
AI Analysis | Feedback
Faeth Therapeutics (Nasdaq: FTH), formerly Sensei Biotherapeutics, Inc., primarily focuses on its lead program, PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway. This therapy is currently being evaluated for advanced endometrial cancer and HR+/HER2- advanced breast cancer. The company's pipeline also includes Solnerstotug (a VISTA inhibitor) and other early-stage oncology candidates such as SNS-102, SNS-103, and SNS-201.
Addressable Markets for Faeth Therapeutics' Main Products:
- PIKTOR for Endometrial Cancer: The global addressable market for endometrial cancer was estimated at USD 26.61 billion in 2023 and is projected to reach USD 49.01 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 5.71% from 2024 to 2034. Other estimates for the global market include USD 30.1 billion in 2024, rising to USD 46.3 billion by 2033 with a CAGR of 4.9% during the forecast period of 2026–2033.
- PIKTOR for HR+/HER2- Advanced Breast Cancer: The global addressable market for metastatic HR+/HER2- breast cancer was valued at USD 14.47 billion in 2025 and is anticipated to reach USD 30.42 billion by 2034, demonstrating a CAGR of 8.61% from 2026 to 2034. The global market for PI3K, AKT, and mTOR pathway inhibitors specifically for breast cancer is estimated at USD 1.5 billion in 2025, with a projected CAGR of approximately 18% from 2025 to 2033.
- Solnerstotug (VISTA Inhibitor): The global market for VISTA-targeted therapies is considered underexplored, and as of now, there are no approved VISTA inhibitors. The first VISTA inhibitor drug approval is anticipated by 2028. Therefore, a quantifiable addressable market size is currently null.
- ImmunoPhage platform, SNS-401-NG, SNS-102, SNS-103, SNS-201, and Merkel cell carcinoma vaccine: Market size information for these specific products and platforms is currently null.
AI Analysis | Feedback
Faeth Therapeutics (FTH), formerly known as Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on developing therapeutics for cancer patients. The company's anticipated revenue growth over the next 2-3 years is expected to be primarily driven by the advancement and potential commercialization of its key pipeline assets.
Here are 3-5 expected drivers of future revenue growth for Faeth Therapeutics:
1. **Clinical Development and Potential Commercialization of PIKTOR in Endometrial Cancer**: Faeth Therapeutics' lead investigational asset, PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, is currently in a Phase 2 trial for advanced endometrial cancer. The company anticipates reporting topline data from this trial in the second half of 2026. Positive clinical outcomes and subsequent regulatory approval could pave the way for its commercialization, generating significant revenue.
2. **Clinical Development and Potential Commercialization of PIKTOR in HR+/HER2- Advanced Breast Cancer**: PIKTOR is also being evaluated in a Phase 1b/2 trial for HR+/HER2- advanced breast cancer. Interim data from this trial is anticipated in 2027. Successful progression through clinical development and potential market entry in this indication would further contribute to the company's revenue stream.
3. **Advancement of Solnerstotug for Solid Tumors**: The company's pipeline includes Solnerstotug, an active monoclonal antibody targeting the immune checkpoint VISTA, which is in clinical Phase 1/2 development for the treatment of solid tumors. Positive clinical trial results and subsequent progression to later stages of development could lead to licensing agreements, partnerships, or eventual market approval, driving future revenue growth.
4. **Development of Other Early-Stage Pipeline Candidates (SNS-102 and SNS-103)**: Faeth Therapeutics also has earlier-stage monoclonal antibody programs, SNS-102 and SNS-103, in its pipeline. Successful preclinical and early clinical development of these candidates could attract further investment, strategic collaborations, or lead to additional product opportunities, contributing to longer-term revenue potential within the 2-3 year timeframe through milestone payments or partnership deals.
AI Analysis | Feedback
Capital Allocation Decisions for Faeth Therapeutics (FTH)
Share Repurchases
- Faeth Therapeutics's 3-month share buyback ratio as of March 2026 was -6.18%, indicating no share repurchases or potential share issuance.
Share Issuance
- Concurrently with its acquisition by Sensei Biotherapeutics in February 2026, Faeth Therapeutics (then Sensei) issued 14,440.395 shares of Series B Preferred Stock in a private placement, which can be converted into 14,440,395 shares of common stock, generating approximately $200 million in gross proceeds.
- The company's shares outstanding increased from 1.26 million in December 2025 to 1.34 million in March 2026, indicating new share issuances during this period.
- Shares outstanding also increased from December 2024 to December 2025.
Inbound Investments
- In February 2026, Sensei Biotherapeutics acquired Faeth Therapeutics and simultaneously closed a private placement financing that resulted in approximately $200 million in gross proceeds from various life sciences funds and institutional investors.
- Faeth Therapeutics raised $25.0 million in a Series A funding round in October 2025, bringing its total capital raised to $92 million. This round was led by S2G Ventures with participation from several other investors.
- Prior to the 2026 acquisition, Faeth Therapeutics secured $67 million in venture capital funding, including a $20 million seed round and a $47 million follow-on round in 2022, primarily backed by Khosla Ventures and Future Ventures.
Outbound Investments
- Faeth Therapeutics reported no significant "Investments And Advances" as of March 2026.
Capital Expenditures
- In the last 12 months (as of June 2026), Faeth Therapeutics' capital expenditures were -$22,000.
- The $25 million strategic raise in October 2025 is intended to advance the Phase 2 endometrial cancer program and expand the throughput for the company's MetabOS™ platform.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.39 |
| Mkt Cap | 68.3 |
| Rev LTM | 6,476 |
| Op Inc LTM | 2,036 |
| FCF LTM | 1,580 |
| FCF 3Y Avg | 850 |
| CFO LTM | 1,826 |
| CFO 3Y Avg | 1,080 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.5% |
| Rev Chg 3Y Avg | 10.3% |
| Rev Chg Q | 11.8% |
| QoQ Delta Rev Chg LTM | 2.9% |
| Op Inc Chg LTM | 1,992.2% |
| Op Inc Chg 3Y Avg | 652.5% |
| Op Mgn LTM | 33.1% |
| Op Mgn 3Y Avg | 22.4% |
| QoQ Delta Op Mgn LTM | -4.8% |
| CFO/Rev LTM | 28.5% |
| CFO/Rev 3Y Avg | 17.4% |
| FCF/Rev LTM | 24.7% |
| FCF/Rev 3Y Avg | 13.5% |
Price Behavior
Price Behavior
| Market Price | $19.92 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 02/04/2021 | |
| Distance from 52W High | -50.3% | |
| 50 Days | 200 Days | |
| DMA Price | $27.69 | |
| DMA Trend | down | |
| Distance from DMA | -28.1% | |
| 3M | 1YR | |
| Volatility | 94.2% | 107.1% |
| Downside Capture | 219.80 | |
| Upside Capture | 109.13 | |
| Correlation (S&P 500) | 14.4% |
FTH Betas & Captures as of 10/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.38 | 1.87 | 0.78 | 0.82 | -0.62 | 1.68 |
| Up Beta | -1.47 | -4.16 | -2.52 | -0.52 | -0.27 | 1.10 |
| Down Beta | -3.03 | -0.48 | 2.83 | 0.34 | 0.20 | 1.20 |
| Up Capture | 270% | 169% | 21% | 117% | 45% | 4% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 8 | 17 | 27 | 44 | 44 | 44 |
| Down Capture | 698% | 434% | 222% | 97% | 57% | 33% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 14 | 26 | 37 | 50 | 50 | 50 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FTH | |
|---|---|---|---|---|
| FTH | 19.7% | 107.1% | 0.90 | - |
| Sector ETF (XLV) | 29.2% | 16.9% | 1.33 | -4.5% |
| Equity (SPY) | 9.5% | 13.6% | 0.41 | 11.7% |
| Gold (GLD) | 3.6% | 28.7% | 0.11 | 11.4% |
| Commodities (DBC) | 37.7% | 21.2% | 1.40 | -2.2% |
| Real Estate (VNQ) | 12.0% | 14.2% | 0.55 | -8.1% |
| Bitcoin (BTCUSD) | -20.8% | 43.3% | -0.42 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FTH | |
|---|---|---|---|---|
| FTH | 3.7% | 107.1% | 0.90 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.36 | -4.5% |
| Equity (SPY) | 11.3% | 17.3% | 0.48 | 11.7% |
| Gold (GLD) | 17.5% | 19.1% | 0.74 | 11.4% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | -2.2% |
| Real Estate (VNQ) | 1.2% | 18.9% | -0.05 | -8.1% |
| Bitcoin (BTCUSD) | 5.9% | 51.5% | 0.29 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FTH | |
|---|---|---|---|---|
| FTH | 1.8% | 107.1% | 0.90 | - |
| Sector ETF (XLV) | 12.2% | 16.8% | 0.60 | -4.5% |
| Equity (SPY) | 14.9% | 18.0% | 0.70 | 11.7% |
| Gold (GLD) | 12.0% | 16.5% | 0.59 | 11.4% |
| Commodities (DBC) | 7.6% | 18.1% | 0.33 | -2.2% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | -8.1% |
| Bitcoin (BTCUSD) | 61.3% | 66.2% | 1.01 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/03/2026 | 10-Q |
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/03/2026 | 10-Q |
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/15/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/13/2021 | 10-Q |
| 12/31/2020 | 03/30/2021 | 10-K |
| 09/30/2020 | 02/04/2021 | 424B4 |
Insider Activity
Updated 11/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 7012026 | 23.50 | 5,000 | 117,492 | 1,097,093 | Form |
| 2 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 7012026 | 24.25 | 7,803 | 189,240 | 1,011,025 | Form |
| 3 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 7012026 | 23.34 | 831 | 19,396 | 790,876 | Form |
| 4 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 6262026 | 24.95 | 6,250 | 155,908 | 824,544 | Form |
| 5 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 6262026 | 26.13 | 9,391 | 245,360 | 700,312 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 7012026 | 23.50 | 5,000 | 117,492 | 1,097,093 | Form |
| 2 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 7012026 | 24.25 | 7,803 | 189,240 | 1,011,025 | Form |
| 3 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 7012026 | 23.34 | 831 | 19,396 | 790,876 | Form |
| 4 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 6262026 | 24.95 | 6,250 | 155,908 | 824,544 | Form |
| 5 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 6262026 | 26.13 | 9,391 | 245,360 | 700,312 | Form |
| 6 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 6242026 | 24.36 | 9,230 | 224,806 | 424,111 | Form |
| 7 | Stephenson, Brian C | Chief Financial Officer | See footnote | Buy | 6242026 | 22.13 | 8,183 | 181,115 | 181,115 | Form |
| 8 | Parikh, Anand Kiran | President and CEO | Direct | Buy | 6242026 | 19.76 | 2,806 | 55,447 | 15,101,264 | Form |
| 9 | Cambrian, Biopharma Inc | Direct | Sell | 6012026 | 20.02 | 25,000 | 500,543 | 2,605,665 | Form | |
| 10 | Peyer, James | Direct | Sell | 6012026 | 20.02 | 25,000 | 500,543 | 2,605,665 | Form | |
| 11 | Millennium, Management Llc | See Footnote | Buy | 5142026 | 33.38 | 1,108 | 36,985 | 4,472,453 | Form | |
| 12 | Millennium, Management Llc | See Footnote | Sell | 5142026 | 31.01 | 8,151 | 252,775 | 4,155,111 | Form | |
| 13 | Millennium, Management Llc | See Footnote | Buy | 5142026 | 31.02 | 1,104 | 34,246 | 4,374,720 | Form | |
| 14 | Millennium, Management Llc | See Footnote | Sell | 5142026 | 31.06 | 1,259 | 39,100 | 4,379,839 | Form | |
| 15 | Millennium, Management Llc | See Footnote | Buy | 5142026 | 35.01 | 2,003 | 70,133 | 5,076,108 | Form | |
| 16 | Millennium, Management Llc | See Footnote | Sell | 5142026 | 32.12 | 7,666 | 246,239 | 4,656,707 | Form | |
| 17 | Millennium, Management Llc | See footnote | Buy | 5142026 | 34.49 | 6,175 | 212,979 | 5,095,317 | Form | |
| 18 | Millennium, Management Llc | See footnote | Sell | 5142026 | 31.65 | 1,150 | 36,396 | 4,675,547 | Form | |
| 19 | Millennium, Management Llc | See footnote | Buy | 5142026 | 28.16 | 6,005 | 169,121 | 4,130,352 | Form | |
| 20 | Millennium, Management Llc | See footnote | Sell | 5142026 | 25.49 | 1,591 | 40,553 | 3,738,119 | Form | |
| 21 | Millennium, Management Llc | See footnote | Buy | 5142026 | 25.86 | 9,533 | 246,495 | 3,766,806 | Form | |
| 22 | Millennium, Management Llc | See footnote | Sell | 5142026 | 26.61 | 888 | 23,632 | 3,876,864 | Form | |
| 23 | Millennium, Management Llc | See footnote | Buy | 5142026 | 26.61 | 15,321 | 407,717 | 3,788,431 | Form | |
| 24 | Millennium, Management Llc | See footnote | Sell | 5142026 | 26.81 | 505 | 13,538 | 3,816,421 | Form | |
| 25 | Millennium, Management Llc | See footnote | Buy | 5142026 | 28.62 | 5,731 | 164,045 | 3,760,352 | Form | |
| 26 | Millennium, Management Llc | See footnote | Sell | 5142026 | 28.12 | 1,857 | 52,220 | 3,694,180 | Form | |
| 27 | Cambrian, Biopharma Inc | Direct | Sell | 12102025 | 8.25 | 6,612 | 54,575 | 1,280,526 | Form | |
| 28 | Peyer, James | See footnote | Sell | 12102025 | 7.96 | 3,507 | 27,903 | 1,234,360 | Form | |
| 29 | Peyer, James | See footnote | Sell | 12102025 | 8.59 | 3,105 | 26,672 | 1,359,402 | Form | |
| 30 | Cambrian, Biopharma Inc | Direct | Sell | 12082025 | 11.50 | 16,295 | 187,390 | 1,855,603 | Form | |
| 31 | Peyer, James | See footnote | Sell | 12082025 | 11.50 | 16,295 | 187,390 | 1,855,603 | Form | |
| 32 | Cambrian, Biopharma Inc | Direct | Sell | 12082025 | 9.06 | 5,000 | 45,300 | 1,609,545 | Form | |
| 33 | Peyer, James | See footnote | Sell | 12082025 | 9.06 | 5,000 | 45,300 | 1,609,545 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 11/5/2026